

sharon Alroy Preis

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Dror Mevorach, M.D. Emilia Anis M.D., M.P.H. Noa Cedar M.P.H. Tal Hasin M.D. Michal Bromberg, M.D., M.P.H. Lital Goldberg M.D., M.P.H. Elchanan Parnasa, M.D. Rita Dichtiar, M.P.H. Yael Hershkovitz M.Sc. Nachman Ash, M.D. Manfred S. Green, M.B., Ch.B., Ph.D. Lital Keinan-Boker, M.D., Ph.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 vaccine in Israeli adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
"Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents"
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Enlivex Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> 10 weekly hours		<i>Description:</i> Chief scientific officer and founder

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Myocarditis After BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- Are you the corresponding author?**
Yes.
 - Please list the other authors' names here.**
Emilia Anis, Noa Cedar, Tal Hasin, Michal Bromberg, Lital Goldberg, Elchanan Parnassa, Rita Dichtiar, Yael Hershkovitz, Nachman Ash, Manfred S. Green, Lital Keinan-Boker, Sharon Alroy-Preis

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16999

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Myocarditis after BNT162b2 COVID-19 Vaccine in Israeli Adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

